Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
NRIX

NRIX - Nurix Therapeutics, Inc. Stock Price, Fair Value and News

$17.87-1.54 (-7.93%)
Market Closed

21/100

NRIX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

21/100

NRIX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$14.85

Target 3M

$16.7

Target 6M

$15.78

NRIX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

NRIX Price Action

Last 7 days

-6.0%

Last 30 days

-7.7%

Last 90 days

39.8%

Trailing 12 Months

-8.6%

NRIX RSI Chart

NRIX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

NRIX Valuation

Market Cap

1.9B

Price/Earnings (Trailing)

-7.15

Price/Sales (Trailing)

22.5

EV/EBITDA

-6.44

Price/Free Cashflow

-7.17

NRIX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$14.85

Target 3M

$16.7

Target 6M

$15.78

NRIX Fundamentals

NRIX Revenue

Revenue (TTM)

84.0M

Rev. Growth (Yr)

2.21%

Rev. Growth (Qtr)

71.99%

NRIX Earnings

Earnings (TTM)

-264.5M

Earnings Growth (Yr)

-33.6%

Earnings Growth (Qtr)

9.49%

NRIX Profitability

EBT Margin

-314.00%

Return on Equity

-49.09%

Return on Assets

-38.43%

Free Cashflow Yield

-13.94%

NRIX Investor Care

Shares Dilution (1Y)

34.19%

Diluted EPS (TTM)

-3.05

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202556.4M88.4M83.7M84.0M
202480.9M62.3M56.4M54.5M
202341.7M60.9M68.6M77.0M
202234.4M38.7M39.2M38.6M
202120.0M22.9M29.0M29.8M
202024.7M19.5M13.0M17.8M
201900031.1M
Get all data in R, Python etc through our Historical Stock Data APIs

About Nurix Therapeutics, Inc.

NRIX
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing DeTIL-0255, a drug-enhanced investigational cell therapy product that uses NX-0255 ex vivo to enhance tumor infiltrating lymphocytes propagation and phenotypic characteristics. The company has a strategic collaboration agreement with Gilead Sciences, Inc. to discover, develop, and commercialize a pipeline of protein degradation drugs for patients with cancer and other challenging diseases; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.
 CEO
 WEBSITEnurixtx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES297

Nurix Therapeutics, Inc. Frequently Asked Questions

NRIX is the stock ticker symbol of Nurix Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Nurix Therapeutics, Inc. is 1.37 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check NRIX's fair value in chart for subscribers.

The fair value guage provides a quick view whether NRIX is over valued or under valued. Whether Nurix Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Nurix Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NRIX.

As of Wed Jan 28 2026, NRIX's PE ratio (Price to Earnings) is -5.61 and Price to Sales (PS) ratio is 16.42. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NRIX PE ratio will change depending on the future growth rate expectations of investors.